


9-8-05

2F.W

Express Mail Label No.: EV473991483US

Date of Deposit: September 6, 2005

Attorney Docket No. 21402-662 (CURA 962)



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS: Floege et al.  
SERIAL NUMBER: 10/665,383 EXAMINER: Not Yet Assigned  
FILING DATE: September 16, 2003 ART UNIT: 1616  
FOR: METHOD FOR THE TREATMENT OF NEPHRITIS USING ANTI-PDGF-DD  
ANTIBODIES

Commissioner for Patents  
P.O. Box 1450  
Washington, D.C. 22313-1450

**TRANSMITTAL LETTER**

Enclosed herewith for filing in the above-identified application please find the following documents:

1. Revocation By Assignees and New Power of Attorney (1 pg)
2. Schedule A (1 pg); and,
3. Return Postcard.

Although Applicants believe no additional fees are due with this submission, the Commissioner is hereby authorized to charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311 (Reference No. 21402-662).

Respectfully submitted,


Ivor R. Elrifi, Reg. No. 39,529  
Naomi S. Biswas, Reg. No. 38,384  
Attorney for Applicants  
c/o MINTZ, LEVIN  
Tel: (617) 542-6000  
Fax: (617) 542-2241  
**Customer No. 55111**

Dated: September 6, 2005

Express Mail Label No.: EV473991483US

Date of Deposit: September 6, 2005

Attorney Docket No. 21401-662 (CURA 962)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ASSIGNEE: CuraGen Corporation and Abgenix, Inc.

SERIAL NUMBER: See Attached Schedule A

FILING DATE: See Attached Schedule A

FOR: See Attached Schedule A

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

REVOCATION BY ASSIGNEES AND NEW POWER OF ATTORNEY

CuraGen Corporation and Abgenix, Inc., companies and owners ("Assignees") of the patents and patent applications listed on the attached Schedule A, hereby revoke any and all former powers of attorney and hereby appoint the attorneys and/or agents associated with Customer Number 55111, as Applicants' attorneys with full power of substitution and revocation to take any and all action necessary with regard to the patent application.

Please address all telephone calls to Ivor R. Elrifi at telephone number 617/348-1747.


Please address all correspondence to Customer No. 55111.

The undersigned is authorized to act on behalf of the Assignees in the above-referenced patent applications.

Respectfully submitted,

Date:


Sep 2<sup>nd</sup> 2005

  
George M. Yalwak  
Director of Intellectual Property  
CuraGen Corporation

Respectfully submitted,

Date:

8/24/05

  
Don Joseph  
Senior Vice President and General Counsel  
Abgenix, Inc.



Schedule A

U.S. APPLICATIONS

Docket No.	Title	Filing Date	Application No.	Assignment Reel and Frame Nos.
21402-661 CURA 961	Antibodies Directed To PDGFD and Uses Thereof	January 7, 2002	10/041,860	R#013168 F#0146
21402-662 CURA 962	Method For the Treatment of Nephritis Using Anti-PDGF-DD Antibodies	September 16, 2003	10/665,383	R# F#
21402-665 CURA 965	Antibodies Against T-Cell Immunoglobulin Domain And Mucin Domain 1 (TIM-1) Antigen and Uses Thereof	March 19, 2004	10/805,177	R#015863 F#0140

TRA 2061200v1